BioCentury | Dec 17, 2019
Clinical News

Axsome continues ascent with Phase III success in depression

...climbing since Oct. 15, when it jumped 13% from $18.24 on early data hinting that REL-1017...
...rather than weeks, but its use is restricted to the in-patient setting. Like Spravato and REL-1017...
BioCentury | Oct 16, 2019
Product Development

Relmada data offer hope of safer option for depression

...Relmada more than doubled its share price Tuesday after reporting Phase II data hinting that REL-1017...
...that can untangle the antidepressant and psychotomimetic effects of ketamine (see “Dissociating Ketamine” ). Though REL-1017...
...call Tuesday that REL-1017 would be administered in an outpatient setting in subsequent clinical trials. REL-1017...
BioCentury | Jan 19, 2018
Tools & Techniques

Synthetic expressions

...1 IL-10 - Interleukin-10 PDX1 (IPF1) - Pancreatic and duodenal homeobox 1 RELA (p65) - v-rel...
...FST) Frataxin (FXN) (FRDA) Heat shock transcription factor 1 (HSF1) Interleukin-10 (IL-10) Pancreatic and duodenal homeobox 1 (PDX1) (IPF1) Utrophin (UTRN) V-rel...
BioCentury | Nov 1, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: October 2017

New Therapeutic Targets and Biomarkers: October 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Oct 17, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Malaria Mosquito studies suggest genetically modifying the insects or feeding them genetically modified bacteria could help prevent transmission of malaria. In Anopheles stephensi mosquitoes fed a Plasmodium falciparum -infected blood meal, midgut overexpression of...
BioCentury | Aug 4, 2016
Product R&D

Antibiotic wisdom

...CEACAM1 ( CD66a ) - Carcinoembryonic antigen-related cell adhesion molecule 1 c- REL (REL) - v-rel reticuloendotheliosis viral oncogene homolog avian...
BioCentury | Jun 1, 2015
Clinical News

Buprenorphine: Phase I started

...Relmada began a crossover, Canadian Phase I trial to compare single doses of oral REL-1028 vs...
...Therapeutics Inc. (OTCQB:RLMD), New York, N.Y. Product: Buprenorphine ( BuTab , BuTab ER ) ( REL-1028...
BioCentury | Oct 2, 2014
Distillery Therapeutics

Indication: Autoimmune disease

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Rheumatoid arthritis (RA) v-Rel reticuloendotheliosis...
BioCentury | Mar 27, 2014
Targets & Mechanisms

Insights into ependymoma

...cases involved a fusion between chromosome 11 open reading frame 95 ( C11orf95 ) and v-rel...
BioCentury | Mar 13, 2014
Distillery Therapeutics

Indication: Cancer

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer V-rel reticuloendotheliosis viral oncogene...
Items per page:
1 - 10 of 31